Puma Biotechnology, Inc.: Breast Neoplasms trials

The registry lists 14 Breast Neoplasms studies with Puma Biotechnology, Inc. as lead sponsor. 1 are open to participants now and 13 have results posted.

Phase 1 6Phase 2 11Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerRecruitingNCT06369285Phase 2
• A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With NeratinibCompletedNCT04366713Phase 2Results posted
• An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamideCompletedNCT02400476Phase 2Results posted
• A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic SettingCompletedNCT01808573Phase 3Results posted
• Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast CancerCompletedNCT01111825Phase 1/2Results posted
• Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast CancerCompletedNCT00915018Phase 2Results posted
• Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerCompletedNCT00878709Phase 3Results posted
• Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast CancerCompletedNCT00777101Phase 2Results posted
• Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast CancerCompletedNCT00741260Phase 1/2Results posted
• Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast CancerCompletedNCT00706030Phase 1/2Results posted
• A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast CancerCompletedNCT00445458Phase 1/2Results posted
• A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast CancerCompletedNCT00398567Phase 1/2Results posted
• Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast CancerCompletedNCT00300781Phase 2Results posted
• Study Evaluating HKI-272 in TumorsCompletedNCT00146172Phase 1Results posted